Rebeca Maria Mejias-Estevez

Dr. Rebeca Maria Mejias-Estevez

University of Seville, Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TBTyesha N. Burks
Tyesha N. Burks
EAEva Andres-Mateos
Eva Andres-Mateos
RMRuth Marx
Ruth Marx
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
CEChristel Van Erp
Christel Van Erp
RCRonald D. Cohn
Ronald D. Cohn
Losartan improves muscle remodeling and protects against immobilization atrophy by mediating pathways critical for muscle homeostasis.

19 November 2012 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
EAEva Andres‐Mateos
Eva Andres‐Mateos
HBHeinrich Brinkmeier
Heinrich Brinkmeier
TBTyesha N. Burks
Tyesha N. Burks
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
DFDaniel C. Files
Daniel C. Files
RCRonald D. Cohn
Ronald D. Cohn
Maintaining skeletal muscle mass is essential for general health and prevention of disease progression in various neuromuscular conditions. Currently, no treatments are available to prevent progressive loss of muscle mass in any of these conditions. Hibernating mammals are protected from muscle atrophy despite prolonged periods of immobilization and starvation. Here, we describe a mechanism underlying muscle preservation and translate it to non‐hibernating mammals. Although Akt has an established role in skeletal muscle homeostasis, we find that serum‐ and glucocorticoid‐inducible kinase 1 (SGK1) regulates muscle mass maintenance via downregulation of proteolysis and autophagy as well as increased protein synthesis during hibernation. We demonstrate that SGK1 is critical for the maintenance of skeletal muscle homeostasis and function in non‐hibernating mammals in normal and atrophic conditions such as starvation and immobilization. Our results identify a novel therapeutic target to combat loss of skeletal muscle mass associated with muscle degeneration and atrophy.

1 April 2012 in Behavioural Brain Research
Verified
Journal Article
Closed access
AAAbby Adamczyk
Abby Adamczyk
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
KTKogo Takamiya
Kogo Takamiya
JYJennifer Yocum
Jennifer Yocum
IKIrina N. Krasnova
Irina N. Krasnova
TWTao Wang
Tao Wang

16 December 2009 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EAEva Andres-Mateos
Eva Andres-Mateos
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
MSMasayuki Sasaki
Masayuki Sasaki
XLXiaojie Li
Xiaojie Li
BLBrian M. Lin
Brian M. Lin
VDValina L. Dawson
Valina L. Dawson
Mutations in theleucine-rich repeat kinase 2(LRRK2) gene are the most common known cause of Parkinson's disease (PD). Whether loss of LRRK2 function accounts for neurodegeneration of dopamine neurons in PD is not known, nor is it known whether LRRK2 kinase activity modulates the susceptibility of dopamine (DA) neurons to the selective dopaminergic toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). To better understand the role of LRRK2 in DA neuronal survival and its role in the susceptibility of DA neurons to MPTP, we generated LRRK2 knock-out (KO) mice lacking the kinase domain of LRRK2. Here, we show that LRRK2 KO mice are viable and have no major abnormalities and live to adulthood. The dopaminergic system is normal in LRRK2 KO mice as assessed via HPLC for DA and its metabolites and via stereologic assessment of DA neuron number in young and aged mice. Importantly, there is no significant difference in the susceptibility of LRRK2 KO and wild-type mice to MPTP. These results suggest that LRRK2 plays little if any role in the development and survival of DA neurons under physiologic conditions. Thus, PD due to LRRK2 mutations are likely not due to a loss of function. Moreover, LRRK2 is not required for the susceptibility of DA neurons to MPTP.

23 January 2004 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
JDJ. Delgado-Jarana
J. Delgado-Jarana
MLM Carmen Limon
M Carmen Limon
MCM. R. Chacón
M. R. Chacón
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
ARA. M. Rincón
A. M. Rincón
TBT. Benítez
T. Benítez

7 March 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RMRebeca Maria Mejias-Estevez
Rebeca Maria Mejias-Estevez
AAAbby Adamczyk
Abby Adamczyk
VAVictor Anggono
Victor Anggono
TNTejasvi Niranjan
Tejasvi Niranjan
GTGareth M. Thomas
Gareth M. Thomas
TWTao Wang
Tao Wang
Glutamate receptor interacting protein 1 (GRIP1) is a neuronal scaffolding protein that interacts directly with the C termini of glutamate receptors 2/3 (GluA2/3) via its PDZ domains 4 to 6 (PDZ4–6). We found an association ( P < 0.05) of a SNP within the PDZ4-6 genomic region with autism by genotyping autistic patients ( n = 480) and matched controls ( n = 480). Parallel sequencing identified five rare missense variants within or near PDZ4–6 only in the autism cohort, resulting in a higher cumulative mutation load ( P = 0.032). Two variants correlated with a more severe deficit in reciprocal social interaction in affected sibling pairs from proband families. These variants were associated with altered interactions with GluA2/3 and faster recycling and increased surface distribution of GluA2 in neurons, suggesting gain-of-function because GRIP1/2 deficiency showed opposite phenotypes. Grip1/2 knockout mice exhibited increased sociability and impaired prepulse inhibition. These results support a role for GRIP in social behavior and implicate GRIP1 variants in modulating autistic phenotype.